Notably, the pancreatic cancer group had a greater frequency of KRAS gene mutation (83.7% vs. 51.3%, p < 0.001) and a greater prevalence of pancreatitis (18.6% vs. 0.9%, p < 0.001) and pancreatic cysts (6.2% vs. 0.2%, p < 0.001) compared to the nonpancreatic cancer group. This evidence concerns the gene KRAS and Pancreatic cysts.